Daratumumab Injection ( DrugBank: Daratumumab )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
16	Crow-Fukase syndrome	1
49	Systemic lupus erythematosus	1

16. Crow-Fukase syndrome

---

Clinical trials : 13 /  Drugs : 18 - (DrugBank : 8) / Drug target genes : 5 - Drug target pathways : 81

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04396496 (ClinicalTrials.gov)	September 22, 2020	15/5/2020	Treatment of POEMS Syndrome With Daratumumab	A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab	POEMS Syndrome	Drug: Daratumumab Injection	University of Arkansas	Janssen Scientific Affairs, LLC	Recruiting	18 Years	N/A	All	10	Phase 2	United States

49. Systemic lupus erythematosus

---

Clinical trials : 946 /  Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04810754 (ClinicalTrials.gov)	June 30, 2021	11/3/2021	An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus	A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Daratumumab Injection	Charite University, Berlin, Germany	Janssen-Cilag G.m.b.H;Labor Berlin-Charité Vivantes G.m.b.H;Deutsches Rheuma-Forschungszentrum Berlin (DRFZ);Charité Clinical Trial Office (CTO)	Not yet recruiting	18 Years	60 Years	All	10	Phase 2	NULL